Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC. Lu S, Kato T, Dong X, Ahn MJ, et al. N Engl J Med 2024;391:585-597.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Lu S, Kato T, Dong X, Ahn MJ, et al. Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC. N Engl J Med 2024;391:585-597.
PMID: 38828946